Clinical

DUBLIN--(BUSINESS WIRE)--The "China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. At present, there are 3 bispecific antibodies which have got…

LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates…

ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor ReSPECT-GBM Phase 2 trial enrollment has begun Update on…

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry…

BEIJING & WALTHAM, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs,…

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors,…

Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET PARIS--(BUSINESS WIRE)--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases,…

MELBOURNE, Australia--(BUSINESS WIRE)--Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, has announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors –…

New Integrated Clinical Site Organization Led by World-Class Clinical Development Experts Provides Greater and More Equitable Access to High-Quality Research NEW YORK--(BUSINESS WIRE)--Grant Avenue Capital, LLC (“Grant Avenue”), a…

SAN DIEGO, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced…